SUBSCRIBE
SUBSCRIBE

Phase I

Policy
Biopharma Update on the Novel Coronavirus: June 5
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 5, 2020.
June 5, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
How COVID-19 is Affecting Clinical Trials and Drug Supplies from Biotech Bay Companies
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
June 4, 2020
 · 
19 min read
 · 
Chelsea Weidman Burke, M.S.
Policy
Biopharma Update on the Novel Coronavirus: June 4
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 4, 2020.
June 4, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
LabCorp Launches Website to Connect Patients with COVID-19 Clinical Trials
The company announced its Covance drug development business was launching COVID-19 Clinical Trial Connect in the U.S. to help people find information on taking part in clinical trials related to COVID-19.
June 3, 2020
 · 
3 min read
 · 
Mark Terry
Drug Development
Biopharma Update on the Novel Coronavirus: June 3
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 3, 2020.
June 3, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Drug Development
Ziopharm Phase I Trial Yields Positive Results for Treatment of rGBM
The main Phase I monotherapy study had a favorable safety profile, showing that Ad+V was safely administered and tolerably in both craniotomy and stereotactic subjects.
May 29, 2020
 · 
3 min read
 · 
Krystle Vermes
Drug Development
Allogene’s ALLO-501 Shows Positive Results in Its Phase I ALPHA Trial
The data, which was presented at the American Society of Clinical Oncology annual meeting, looked into the use of ALLO-501 for relapsed/refractory non-Hodgkin lymphoma.
May 29, 2020
 · 
3 min read
 · 
Krystle Vermes
BioForest
Clinical Catch-Up: May 25-29
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look.
May 29, 2020
 · 
10 min read
 · 
Mark Terry
Drug Development
Biopharma Update on the Novel Coronavirus: June 1
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 1, 2020.
May 28, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: May 29
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 29, 2020.
May 28, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Load More
PRESS RELEASES
Drug Development
ImmunAbs Announces Conclusion of Phase 1 Clinical Trial, Revealing Positive Topline Results
March 11, 2024
 · 
1 min read
Drug Development
Pelage Presents Late-Breaking Data at AAD 2024 Meeting Demonstrating PP405 Activates Human Hair Follicle Stem Cells Ex Vivo and in Phase 1 Clinical Study
March 9, 2024
 · 
4 min read
Drug Development
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
March 8, 2024
 · 
8 min read
Drug Development
Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye
March 8, 2024
 · 
5 min read
Drug Development
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
March 8, 2024
 · 
5 min read
Drug Development
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
March 7, 2024
 · 
6 min read
Drug Development
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
March 7, 2024
 · 
7 min read
Drug Development
Neurona Therapeutics Announces Presentation of Updated Clinical Data at the Upcoming American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001
March 7, 2024
 · 
4 min read
Drug Development
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson’s patients
March 7, 2024
 · 
6 min read
Business
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
March 7, 2024
 · 
8 min read
Drug Development
Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-driven Solid Tumors
March 7, 2024
 · 
5 min read
Drug Development
Verismo Therapeutics Announces Opening of Second Clinical Site for STAR-101 Phase 1 Trial
March 7, 2024
 · 
2 min read
Drug Development
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
March 7, 2024
 · 
9 min read
Drug Development
NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
March 7, 2024
 · 
5 min read
Drug Development
City of Hope-developed Chimeric Antigen Receptor (CAR) T Cell Therapy Shows Clinical Activity in Patients With Aggressive Brain Tumors in a Phase 1 Trial
March 7, 2024
 · 
8 min read
Drug Development
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency
March 6, 2024
 · 
10 min read
Drug Development
OnCusp Therapeutics Announces First Patient Dosed in Phase 1 Trial of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
March 6, 2024
 · 
3 min read
Drug Development
Syncromune® Inc. to Present Initial Clinical Data from SYNC-T™ SV-102 Phase 1 as a Late-Breaker at the American Association for Cancer Research Annual Meeting 2024
March 6, 2024
 · 
5 min read
Drug Development
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
March 6, 2024
 · 
5 min read
Drug Development
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
March 6, 2024
 · 
6 min read
Load More